A consumer-facing explainer from ABC17NEWS has clarified the current regulatory status of six peptides recommended for the FDA’s 503A Bulks List, confirming that no legal change has yet taken effect despite a July 2026 advisory committee vote.
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted in July 2026 to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for addition to the 503A Bulks List, while rejecting Emideltide. However, the ABC17NEWS report emphasizes that the FDA must still complete formal rulemaking before compounding pharmacies can legally prepare any of these peptides for prescriptions.
The report also notes that each of the six recommended peptides has limited human studies and is primarily researched in rodents and other animal models, and that products sold online for research use remain unapproved for human use.
What happened
In July 2026, the PCAC — a federal advisory committee that makes recommendations to the FDA on compounding matters — voted to recommend six peptides for inclusion on the 503A Bulks List. The list governs which bulk drug substances compounding pharmacies may use to prepare medications under Section 503A of the Federal Food, Drug, and Cosmetic Act.
The six recommended peptides are:
- BPC-157
- KPV
- TB-500
- MOTS-c
- Epitalon
- Semax
The committee rejected Emideltide.
The ABC17NEWS explainer, published September 13, 2026, walks consumers through the FDA’s drug safety review process and clarifies that a PCAC recommendation is not the same as a final regulatory action. The FDA must still complete formal rulemaking before any of these peptides can be legally compounded under 503A.
Why it matters
The report reinforces a persistent source of confusion in the peptide market: the gap between an advisory committee recommendation and an actual change in federal regulation. Until the FDA finalizes rulemaking, compounding pharmacies cannot legally prepare these six peptides for prescriptions, regardless of the July vote.
For consumers, this means pharmacy access to these compounds remains unavailable through legitimate prescription channels. For telehealth platforms and compliance teams, the distinction matters operationally — offering these peptides before rulemaking is complete could carry legal risk.
The ABC17NEWS report also underscores the limited clinical evidence behind the six recommended peptides. According to the explainer, each has limited human studies and is primarily researched in rodents and animals. Products marketed online as research use only remain unapproved for human use.
What to watch next
- Whether the FDA initiates formal rulemaking proceedings for any or all of the six recommended peptides
- How the FDA addresses the rejected Emideltide recommendation
- Whether additional PCAC meetings are scheduled to review other peptide substances
- How compounding pharmacies and telehealth platforms respond to the ongoing regulatory uncertainty
Sources
- ABC17NEWS — How the FDA reviews drug safety as emerging peptide therapies come to its table
- Biotech Research Intelligence — FDA’s September 2026 peptide vendor sweep
Industry information only. Not medical or legal advice.
